Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth

June 14, 2018 updated by: Gabriele Saccone, Federico II University

Spontaneous preterm birth (SPTB) remains the number one cause of perinatal mortality in many countries, including the United States. In singleton gestations a short cervical length (CL) on transvaginal ultrasound (TVU) has been shown to be a good predictor of SPTB.

The cervical pessary is a silicone device that has been used to prevent SPTB. The efficacy of cervical pessary has been assessed in several populations including singletons with short CL, unselected twins, twins with a short CL, and triplet pregnancies. Several randomized clinical trials (RCTs) have been published, and several are ongoing. However, no consensus on the use of cervical pessary in pregnancy or guidelines for management have been assessed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

300

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Napoli, Italy, 80129
        • Gabriele Saccone

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • 18-50 years of age
  • Singleton pregnancy (limits the participants to female gender)
  • Short cervical length (less than or equal to 25 mm) on second trimester transvaginal ultrasound at 18-23 6/7 weeks gestation

Exclusion Criteria:

  • Multiple gestation
  • Prior spontaneous preterm birth 16-36 6/7 weeks
  • Ruptured membranes
  • Lethal fetal structural anomaly
  • Fetal chromosomal abnormality
  • Cerclage in place (or planned placement)
  • Vaginal bleeding
  • Suspicion of chorioamnionitis
  • Ballooning of membranes outside the cervix into the vagina or CL = 0 mm on transvaginal ultrasound
  • Painful regular uterine contractions
  • Placenta previa

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cervical Pessary
The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
No Intervention: No intervention
No pessary No pessary will be used. Subjects will receive standard obstetrical management

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spontaneous preterm birth (SPTB) <34 weeks
Time Frame: Less than 34 weeks gestation
Spontaneous preterm delivery less than 34 weeks of gestation
Less than 34 weeks gestation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SPTB <37w
Time Frame: Less than 37 weeks gestation
Less than 37 weeks gestation
SPTB <32w
Time Frame: Less than 32 weeks gestation
Less than 32 weeks gestation
SPTB <28w
Time Frame: Less than 32 weeks gestation
Less than 32 weeks gestation
Gestational age at delivery
Time Frame: Time of delivery
Time of delivery
Latency
Time Frame: time of delivery
interval from randomization to delivery in days
time of delivery
preterm premature rupture of membranes
Time Frame: Less than 34 weeks gestation
Less than 34 weeks gestation
Type of delivery
Time Frame: time of delivery
Cesarean delivery, operative vaginal delivery and spontaneous vaginal delivery
time of delivery
Maternal side effects
Time Frame: Time of delivery
Vaginal discharge, bacterial vaginosis
Time of delivery
Birth weight
Time Frame: Time of delivery
Time of delivery
Neonatal death
Time Frame: Between birth and 28 days of age
Between birth and 28 days of age
perinatal death
Time Frame: fetal death after 20 weeks
either fetal mortality or neonatal death
fetal death after 20 weeks
Composite adverse perinatal outcome
Time Frame: Between birth and 28 days of age
Includes necrotizing enterocolitis, Intraventricular hemorrhage (grade 3 or higher), respiratory distress syndrome, bronchopulmonary dysplasia (BPD), retinopathy, blood-culture proven sepsis, and neonatal death
Between birth and 28 days of age
Chorioamnionitis
Time Frame: Time of delivery
Time of delivery
Adminssion to neonatal intensive care unit
Time Frame: Between birth and 28 days of age
Between birth and 28 days of age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2016

Primary Completion (Actual)

May 1, 2017

Study Completion (Actual)

July 1, 2017

Study Registration Dates

First Submitted

March 6, 2016

First Submitted That Met QC Criteria

March 17, 2016

First Posted (Estimate)

March 23, 2016

Study Record Updates

Last Update Posted (Actual)

June 18, 2018

Last Update Submitted That Met QC Criteria

June 14, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 213/2015

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Birth

Clinical Trials on Cervical pessary

Subscribe